EGFR and ovarian carcinoma: In the MAPK pathway, the use of EGFR inhibitors to ovarian cancer has seen limited success in clinical trials, possibly attributed to the scarcity of EGFR mutations in ovarian cancer which the inhibitor targets [87–89].